Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -1.220% | -2.633% | -3.857% | -0.080% | -29.386% | -33.159% | -41.972% |
| Opko Health Inc. | 3.090% | 6.598% | 1.978% | -23.769% | -8.274% | -21.161% | -71.371% |
| Amicus Therapeutics Inc. | -2.510% | 0.164% | 0.164% | 103.667% | 1.833% | 20.990% | 58.701% |
Comments
News
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) in a February 17, 2026, SEC filing, with an estimated transaction value of $9.31 million